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The level of cyclic AMP in the epidermis rapidly in-
crease within 15 min after separation from the in vivo 
condition. This phenomenon is the so-called "ischemic 
effect." In order to elucidate the possible mechanism of 
the ischemic effect, the effects of melittin and mepacrine 
on the ischemic condition of the skin were studied. Mel-
ittin a stimulator of phospholipase A2, lessened the 
incr;ase of cyclic AMP, while mepacrine, an inhibitor 
of phospholipase A2, potentiated the increase of cyclic 
AMP during the ischemic condition. The overall results 
suggest that phospholipase A2 may play an important 
role in the induction of the ischemic condition through 
membrane alteration. 
Kakiuchi and Rail reported t hat the int race llular cyclic AMP 
of rabbit cerebral cortex rapidly increased within 2 min after 
decapitation and rapidly decreased to the initial level within 5 
min [1]. A similar. phenomenon has been shown in cerebellum 
and heart [2]. Yoshikawa et a! reported t hat t his "ischemic 
effect" occurred when t he skin was removed from a pig by a 
keratome. This phenomenon was not prevented by the prior 
addit ion of the ,6-antagonist, propranolol [3]. Furthermore, this 
phenomenon was eliminated by freezing the skin before surgical 
procedures. Murray et a! demonstrated t hat the accumulation 
of cyclic AMP was greatly decreased in newborn mouse skin , 
or in adult skin treated with t he tumor promotor, 12-0-tetra-
decanoyl-phorbol-13-acetate [ 4]. . 
Although several investigators have proposed that t he IS -
chemic effect is due to hypoxia, a neurotransmitter [5], the 
decrease of ATP [6], or the redox state change [7], t he precise 
mechanism to induce the ischemic effect was not fully under-
stood. 
The present studies were designed to investigate theyossib~e 
role of phospholipase A2, a membrane enzyme, on the 1schem1c 
effects in the skin by treating with melittin , a stimulator of 
phospholipase A2, and mepacrine, an inhibitor of phospholi-
pase A2. 
MATERIALS AND METHODS 
Domestic pigs weighing 6- 7 kg were a nesthetized i.p. with Nembutal 
(20- 30 mg/kg). After shaving a nd washing t he skin with saline, 5 f.J.g/ 
ml of meli t tin and 0.5 mg/ml of mepacr ine (or 0.1% tetracaine) were 
injected subcutaneously into t he p ig dorsal skin. Thirty minutes late r, 
the skin slices of each injected area were taken wi t h a Castroviejo 
keratome set at a 0.2- mm depth. Each keratome slice of the skin was 
quick-frozen wit h dry ice plates after being kept at room temperature 
for 2 min . The contro l skin was also taken from the back afte r freezing 
wit h dry ice plates. In tracellular cyclic AMP level was determined by 
the radioimmunoassay method of Steiner et al [8] using a cyclic AMP 
kit. Cyclic AMP phosphodiesterase activity was determined by the 
method of lizuka et a l [9]. 
Melittin and mepacrine were purchased from Sigma Chemical Co., 
St. Louis, Missouri . Tetracaine was a gift from Kyorin Pharmaceut ic 
Co., Tokyo, and cycl ic AMP assay kits were obtained from Yamasa 
Shoyu Co., Tokyo. [3H)cyclic AMP was purchased from New E ngland 
Nuclear Co., Boston, Massachusetts. 
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RESULTS 
It has been documented that the accumulation of cyclic AMP 
induced by the ischemic effect is prevented by freezing the skin 
before surgical procedures. The pig skin was obtained by a 
keratome set at a depth of 0.2 mm after freezing the skin with 
dry ice plates. Skin slices thus obtained were kept at room 
temperature (they completely thawed within 30 s), and frozen 
again at various t ime intervals. The intracellular cyclic AMP 
level of each sample was determined as shown in Table I. No 
significant change of cyclic AMP level was detected up to 30 
min after the skin had been kept at room temperature. No 
ischemic effect was observed either in the light ly frozen or in 
the thawed skin which had been completely frozen in vivo. 
Melittin , a stimulator of phospholipase A2, or mepacrine, an 
inhibitor of phospholipase A2, was injected intradermally into 
the pig dorsal skin under Nembutal anesthesia. The ski_n slices 
previously injected were obtained by a ke_ratome 30 mm_ after 
injection and kept at room temperature to mduce the ma~1mu':l 
ischemic condition. As shown in Table II, the level of cycl1c 
AMP in the melittin -injected skin was 5.17 pmol/mg protein, 
while t hat in the saline-injected skin was 8.26 pmol/ mg protein. 
The ischemic effect of the melittin-injected skin was less re-
markable than that of the saline-injected skin . On the other 
hand, the level of cyclic AMP in the mepacrine-injected skin 
was 50% higher than that in the saline-injected skin. Mepacrine 
seemed to potentiate t he ischemic effect in the skin. 
Table III demonstrates the effects of melittin and mepacrine 
TABLE I. Changes of intracellular cyclic AMP level after thawing 
frozen skin slices 
0 min (freeze) 
0.5 
1 
3 
5 
10 
15 
30 
cAMP 
(pmol/ mg protein) 
1.2 ± 0.31 
0.9 ± 0.60 
1.3 ± 0.47 
1.5 ± 0.23 
0.9 ± 0.28 
1.4 ± 0.50 
1.2 ± 0. 29 
1.0 ± 0.33 
(n = 3) 
Each frozen sample was t hawed at room temperature a nd refrozen 
wih dry ice at indicated t ime intervals. The level of cyclic AMP was 
determined as described in Materials and Methods. n = Number of 
sainples; 0 min indicates frozen skin slices. 
TABLE II. Melittin and mepacrine effect on iscemia effect 
Control 
Saline 
Meli ttin 
Mepacrine 
cAMP 
(pmol/ mg prote in) 
0.98 ± 0.28 
8.26 ± 0.37 
5. 17 ± 0.42 
12.28 ± 1.26 
(n = 8) 
Saline vs meli ttin p < 0.001 
Saline vs mepacrine 0.005 < p < 0.01 
One mililiter of saline, melittin (5 f.J.g/ml) and mepacrine (0.5 mg/ 
ml) were injected in t radermally. Skin slices of each injected a rea were 
taken by keratome 30 min late r. Skin slices thus obtained were kept at 
room temperature for 2 min and frozen. The level of cyclic AMP was 
determined as described in Materials and Methods. n = Number of 
samples. 
420 
Nov. 1983 
TABLE Ill. The effects of melittin and mepacrine on phosphodiesterase 
activities 
High Km 
Control 
Meli ttin 
Mepac rine 
LowKm 
Control 
Meli ttin 
Mepacrine 
Phosphodieste rase 
(POE) activity 
pmol/ min/ mg protein 
243 ± 23 
258 ± 31 
239 ± 25 
29 ± 7.2 
33 ± 5.8 
31 ± 4.9 
(n = 4) 
One millilite r of saline, melittin (5 llg/ml) a nd mepacrine (0.5 mg/ 
ml) were injected in t radermally. Skin slices of each injected site were 
taken by a keratome 30 min late r. POE activi t ies were determined as 
described in materials and methods. n =Number of samples. 
on cyclic AMP phosphodiesterase activities. There were no 
significant differences of phosphodiesterase activities among 
the control, saline, melittin, and mepacrine treatment. 
DISCUSSION 
Previous reports indicate that the increase of intracellular 
cyclic AMP and t he decrease of intracellular cyclic GMP were 
observed in t he ischemic condition of the sk in [3,10), but the 
precise mechanism is not fu lly understood. The ischemic effect 
could be prevented by freezing t he skin in vivo. Furrthermore, 
thawing frozen skin slices or freezing skin slices superficially 
in vivo failed to induce the ischemic effect. These results 
suggest that the freezing procedure fixes cells and t he thawing 
procedure destroys cell membrane with biochemical and 
biologic alterations, which may result in the prevention of t he 
ischemic effect. 
Meli ttin, a stimulator of phospholipase A2, lessened t he 
increase of cyclic AMP, while mepacrine, an inhibitor of phos-
pholipase A2, potentiated the increase of cyclic AMP. Although 
phospholipase A2 activities were not measured in this experi -
ment, it is reported that melittin stimulates phospholipase A2 
and mepacrine inhibits phospholipase A2 in various other 
tissues [11 ,12]. Since neither melittin nor mepacrine altered 
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cyclic AMP phosphodiesterase activities, it is conceivable to 
speculate that phospholipase A2 may contribute to t he induc-
tion of the ischemic effect of the skin, probably through the 
adenylate cyclase complex. 
The overall results suggest that these agents, melittin and 
mepacrine, do insert into the cell membrane and change the 
activation of adenylate cyclase, one increasing it, i.e., mepa-
crine, and one decreasing it, i.e., melittin. 
Mepacrine also recent ly has been shown to reverse refracto-
riness after epinephrine treatment, so it does seem to recouple 
the cell membrane receptor to adenylate cyclase, while melittin 
would seem to do the opposite. 
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